Prognostic Factors and Outcome of Patients with Adult Acute Lymphoblastic Leukemia Treated with the Hyper-CVAD Regimen: A Retrospective Study
Aim. The Hyper-CVAD regimen has shown promising results for adult patients with acute lymphoblastic leukemia (ALL), as designed by the MD Anderson Cancer Center (MDACC). This treatment has resulted in a complete remission rate of 92% and a 5-year overall survival of 38%. However, given the diversity...
Saved in:
Main Authors: | Zahra Malakoutikhah, Farzaneh Ashrafi, Ali Derakhshandeh |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2023-01-01
|
Series: | Advances in Hematology |
Online Access: | http://dx.doi.org/10.1155/2023/5593635 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Retinal and Preretinal Hemorrhages in a Patient Receiving Hyper-CVAD Chemotherapy for T-Cell Acute Lymphoblastic Leukemia
by: Krishi Peddada, et al.
Published: (2018-01-01) -
Osteoporosis in Acute Lymphoblastic Leukemia
by: Lestry Fibriani, et al.
Published: (2019-09-01) -
An Adult Patient with Systemic Mastocytosis and B-Acute Lymphoblastic Leukemia
by: Theodoros Iliakis, et al.
Published: (2014-01-01) -
Acute Neurotoxicity in Children Treated for Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma: A 10-Year Single-Centre Experience
by: Izabela Kranjčec, et al.
Published: (2024-12-01) -
Secondary neoplasms in survivors of pediatric acute lymphoblastic leukemia and lymphoblastic lymphoma: a single-center, retrospective study
by: Eri Ushida, et al.
Published: (2025-01-01)